For most of this year, Jim O'Neill looked like a man who would get the job. President Donald Trump nominated him on March 2 to run the National Science Foundation, the independent agency that pays for much of the country's basic research. The Senate was Republican. His party chaired the committee that would vet him. On Wednesday morning in Washington, the committee was finally due to vote.
It never did. At the start of a business meeting of the Senate Health, Education, Labor and Pensions Committee, its chairman, Senator Bill Cassidy of Louisiana, a Republican and a physician, announced that the vote on O'Neill had been cancelled. O'Neill "didn't have the votes," Cassidy told a leading science journal afterwards. The committee went on to approve three other Trump nominees along party lines. O'Neill's name was simply not on the list.
There was no public hearing, no roll call and no floor fight. The nomination of the man who had run the Centers for Disease Control and Prevention for five months ended quietly, struck from a chairman's agenda. To understand why, it helps to look at the unusual path that brought O'Neill to the edge of the country's top science job, and at the record he built along the way.
O'Neill is not a scientist, and he has never claimed to be one. He studied humanities at Yale, where he graduated in 1990 and served as general manager of its precision marching band, and later earned a master's degree in humanities at the University of Chicago. His early career was political: he worked for Senator Kay Bailey Hutchison of Texas and in the White House, then joined the Department of Education in 2001.
From 2002 he spent six years at the Department of Health and Human Services under President George W. Bush. He began as director of the speech and editorial division, writing and editing the secretary's speeches, and rose to principal associate deputy secretary, with a policy portfolio that included the Food and Drug Administration, the National Institutes of Health and the government's biodefence research office. It was a classic Washington insider's education in how the health bureaucracy works.
Then he left for Silicon Valley. From 2008 to 2012 he was a managing director at Clarium Capital, the hedge fund run by the billionaire investor Peter Thiel, and also ran the Thiel Foundation. He helped found the Thiel Fellowship, which pays young people $100,000 to leave college and build companies, and Breakout Labs, which funds early biotech and food science firms. From 2012 to 2019 he was a managing director at Mithril Capital, a venture fund co-founded by Thiel whose portfolio has included Palantir Technologies. He also sat for a time on the board of the Seasteading Institute, which promotes floating communities beyond the reach of national governments.
In 2019 he became chief executive of the SENS Research Foundation, a nonprofit devoted to rejuvenation and anti-aging research, and stayed until July 2021. He describes himself as a libertarian, and his views on regulation were never hidden. In a 2009 talk he argued that "because there's not a free market in health care, people are suffering very significant health consequences." In a 2014 speech he proposed approving drugs once their makers had shown safety and letting people "start using them, at their own risk," adding: "Let's prove efficacy after they've been legalized." Those words made him a contender for FDA commissioner when Trump's first transition team was hiring in 2016, though he was not nominated.
The second Trump administration brought him back. Trump picked him in November 2024 to be deputy secretary of Health and Human Services under Robert F. Kennedy Jr., and the Senate confirmed him on June 5, 2025, by 52 votes to 43. He took office four days later as the department's second-ranking official.
Within three months he had a second job. In late August 2025, Susan Monarez was removed as CDC director barely a month after the Senate confirmed her. Monarez later said she was pushed out for refusing to rubber-stamp vaccine recommendations that lacked evidence and for refusing to fire staff without cause. On August 28, O'Neill became acting director while keeping his deputy secretary post.
His signature is on two of the most contested public health decisions of the past year. On December 16, 2025, he approved a recommendation from the CDC's vaccine advisory committee, whose members Kennedy had handpicked, ending the universal advice that every newborn receive a hepatitis B vaccine dose within 24 hours of birth. For babies of mothers who test negative, the decision became a matter for parents and doctors, with a first dose suggested no earlier than two months. "We are restoring the balance of informed consent to parents whose newborns face little risk of contracting hepatitis B," O'Neill said. Medical groups pushed back hard, warning that the change upended about 30 years of established practice.
On January 5, 2026, acting on a presidential memorandum, he signed a decision memo accepting a review of the childhood vaccine schedule that compared the United States with 20 developed countries. The review noted that Denmark immunises children against 10 diseases while the American schedule covered 18 in 2024, and the list recommended for every child now names 11 diseases, leaving other vaccines to narrower recommendations. "The data support a more focused schedule that protects children from the most serious infectious diseases while improving clarity, adherence, and public confidence," O'Neill said at the time. Measles, polio and whooping cough stayed on the universal list.
Supporters saw these moves as overdue respect for parental choice and a correction to a schedule that had grown without much public debate. Critics saw a politically appointed nonscientist signing off on changes the scientific mainstream opposed. On February 13, 2026, O'Neill left both health posts. Less than three weeks later, he was nominated to lead the science foundation.
The agency he was chosen to lead is in unusual turmoil. It has not had a Senate-confirmed director since April 2025, when Sethuraman Panchanathan, whom Trump himself had appointed in 2019, resigned with a year left on his six-year term. In April this year Trump removed every member of the National Science Board, the presidentially appointed body that oversees the foundation. The official performing the director's duties, chief of staff Brian Stone, announced in October that he will retire at the end of this year.
Money has been just as unsettled. A leading science journal reported in June that the foundation was cutting hundreds of traditional basic research programmes by 20 to 30 percent or more, even though its overall budget was down only about 3 percent, apparently to free up funds for a new $1.5 billion initiative to turn discoveries into products. A watchdog group that tracks federal grants calculated that by mid-June the agency had made only about one-eighth as many new awards as at the same point a year earlier. And on November 16, the Supreme Court declined for now to intervene in a case in which lower courts ordered the foundation and other agencies to restore hundreds of research grants cancelled over terms such as "climate change" and "equity."
This was the backdrop when scientists' groups lined up against O'Neill. On Monday, Gretchen Goldman, president of the Union of Concerned Scientists, said "the head of the nation's premier science agency should be a scientist or an engineer in their own right," and accused O'Neill of "running political interference in scientific decisions" at the health department. The same day, Senator Tammy Baldwin of Wisconsin, a senior Democrat on the committee, and Senator Maria Cantwell of Washington, the top Democrat on the commerce committee, asked Cassidy to hold a hearing first. "The committee and the public should hear directly from Mr. O'Neill about how he would restore confidence in the agency, rebuild the NSF workforce, and ensure that the United States remains a global leader in science," they wrote.
Cassidy's own reasons, set out in his opening statement on Wednesday, went to O'Neill's record at the CDC rather than his résumé. "As acting CDC director, Mr. O'Neill did not do enough to stand up for science against irresponsible decisions and statements from Secretary Kennedy," he said. "His role in the firing of Dr. Susan Monarez raised further concerns about the independent judgment he would bring to NSF. Several of the committee members had those concerns." He added a personal note: "I like Jim personally, but this job requires leadership and fortitude in standing up for what is right."
Speaking to a reporter afterwards, Cassidy tied the decision to fears that the foundation could lose its 76-year-old independence inside the executive branch. "We need someone who is willing to resist when the administration is pressuring you to do something that is inappropriate," he said. "He's not a scientist, and there are concerns he wouldn't do that." He declined to say how he himself would have voted.
The timing made the rebuke louder. Only a day earlier, the White House had withdrawn Heidi Overton, its nominee for FDA commissioner, saying she lacked the votes. Cassidy disputed that, saying in a post online that he believed she would have cleared both the committee and the full Senate. He said antiabortion senators had sought assurances from the White House about the agency's direction, and that the administration chose to withdraw her rather than make them. In the space of two days, two of the administration's top science and health picks fell short in a committee its own party controls.
The White House has not withdrawn O'Neill's nomination. But the calendar has done most of the work. Democrats take control of the Senate in January 2027, and a nomination that is not confirmed by the end of this Congress would have to be sent again. Democrats on the committee opposed O'Neill, so the path back for him is very narrow. A science journal that covers the agency closely concluded that his chances of ever getting the job are now "essentially nil."
What happens next matters well beyond one résumé. The foundation spends roughly $9 billion a year on the research that feeds universities, start-ups and the technologies, from artificial intelligence to quantum computing, that both parties say they want America to lead. Its next director will be chosen by a president who has sought deep cuts and confirmed by a Senate run by the opposition, with an oversight board that no longer exists and an acting chief who is about to leave.
For O'Neill, the arc is striking. He spent two decades moving between government and the investment world, arguing that regulators should step aside and let innovation move faster. He reached the second-highest post in the country's health department and ran its disease agency through one of the most turbulent periods in its history. And then, at the door of the job built most directly around science, a Republican doctor decided that the record he made at the CDC was the reason to keep it closed.
